Analyst Reco. United Therapeutics Corporation

Equities

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2026-04-17 EDT			5-day change	1st Jan Change
588.38 ^USD	+1.36%		+2.91%	+20.76%

04-17	United Therapeutics Insider Sold Shares Worth $5,771,765, According to a Recent SEC Filing	MT
04-17	United Therapeutics Insider Sold Shares Worth $5,483,484, According to a Recent SEC Filing	MT

Analyst Reco.

04-10	Raymond James Initiates United Therapeutics at Outperform	MT
04-07	RBC Capital Adjusts Price Target on United Therapeutics to $700 From $643, Maintains Outperform Rating	MT
03-05	United Therapeutics Seen as Top Pick on Multiple Near-Term Catalysts, UBS Says	MT
03-05	UBS Adjusts Price Target on United Therapeutics to $705 From $655, Maintains Buy Rating	MT
02-26	United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says	MT
02-26	Oppenheimer Adjusts United Therapeutics Price Target to $600 From $575, Maintains Outperform Rating	MT
02-26	RBC Raises Price Target on United Therapeutics to $643 From $587, Keeps Outperform Rating	MT
01-06	UBS Adjusts Price Target on United Therapeutics to $645 From $600, Maintains Buy Rating	MT
11-06	UBS Adjusts Price Target on United Therapeutics to $600 From $580, Maintains Buy Rating	MT
25-10-31	Analyst recommendations: Comcast, Roblox, Alphabet, Reddit, Western Digital…
25-10-09	BofA Cuts Price Target on United Therapeutics to $461 From $463	MT
25-09-29	UBS Adjusts United Therapeutics Price Target to $580 From $560, Maintains Buy Rating	MT
25-09-26	United Therapeutics' Tyvaso Success in IPF to Unlock Big Market Opportunity, RBC Says	MT
25-09-26	RBC Initiates United Therapeutics at Outperform With $569 Price Target	MT
25-09-10	Analyst recommendations: Apple, Oracle, Synopsys, Robinhood Markets, American Electric Power...
25-09-05	United Therapeutics' Tyvaso Win in IPF Clears Path for More Revenue, Oppenheimer Says	MT
25-09-05	Oppenheimer Adjusts Price Target on United Therapeutics to $575 From $510, Maintains Outperform Rating	MT
25-09-04	UBS Adjusts Price Target on United Therapeutics to $560 From $415, Maintains Buy Rating	MT
25-09-03	Analyst recommendations: Accenture, Chipotle, Kraft, Lucid Group, Thor Industries…
25-09-02	TD Cowen Adjusts Price Target on United Therapeutics to $500 From $400, Maintains Buy Rating	MT
25-08-13	UBS Adjusts United Therapeutics Price Target to $415 From $385, Maintains Buy Rating	MT
25-07-14	United Therapeutics Offers Favorable Profile Ahead of Key Data, Oppenheimer Says	MT
25-06-30	UBS Adjusts Price Target on United Therapeutics to $385 From $410, Maintains Buy Rating	MT
25-06-02	Cantor Fitzgerald Initiates United Therapeutics at Overweight With $405 Price Target	MT
25-04-21	BofA Securities Upgrades United Therapeutics to Neutral From Underperform	MT